The coverslips were examined using a light microscope to determin

The coverslips were examined using a light microscope to determine the adherence of

the strains. Categories (+++ to −) were assigned through comparison of the size of the microcolonies. Contact hemolysis assay was performed as previously described with slight modification (32). Bacterial strains were grown overnight in BHI broth at 30 C. The cultures were then diluted 1:100 into 5 ml of DMEM and shaken at 250 rpm for 100 min in 15-ml conical polypropylene tubes at 37 C. Next, the bacterial aggregates were centrifuged at 2,000 × g for 15 min. The pellets were resuspended into 5 ml of DMEM, 50 μl of which was placed onto 96-well microtiter plates and monitored for viable bacteria at an optical wavelength of Dactolisib research buy 600 nm. 50 μl of a 25% sheep RBC (Nippon Biotest Laboratories Inc., Tokyo, Japan)-DMEM suspension was added and this was centrifuged at 1,000 × g for 15 min to form a close EPEC-RBC contact. After 2 hr of incubation at 37 C, CP-868596 in vivo bacterium-RBC pellets were gently resuspended to facilitate the release of hemoglobin. Cells were centrifuged at 1,000 × g for 15 min, and the supernatant was monitored for released hemoglobin at an optical wavelength of 550 nm. Similarly-treated uninfected RBCs were used as a spectrophotometric zero. The hemolysis ratio was calculated using E2348/69 as a standard.

RT-PCR was used to analyse the transcriptional expression of the bfpA gene indicating expression of the bundlin. Overnight

bacteria cultures were diluted 1:100 in DMEM F-12 broth and grown to the mid-logarithmic phase (OD600= 0.5) at 37 C with shaking. Cultures were pelleted by centrifugation at 13,000 × g for 10 min, and RNA was isolated using TRIzol® Reagent (Invitrogen, Faraday Avenue, CA, USA) according to the manufacturer’s instructions. Total RNA (1 μg) and 60 μM of random hexamers (Roche, Mannheim, Germany) were incubated for 10 min at 65 C, immediately cooled on ice and then reverse transcribed in a final volume of 20 μl-containing 1 mM of deoxynucleotide mix, 20 U of RNase inhibitor, Transcriptor RT reaction Tau-protein kinase Buffer 1× and 10 U of Transcriptor reverse transcriptase (Roche)-that was reacted for 30 min at 55 C. PCR amplification of cDNA was performed with an initial denaturation step of 5 min at 94 C, followed by 19 cycles of 30 sec at 94 C, 1 min at 55 C and 1.5 min at 72 C, and finishing with one cycle of 10 min at 72 C, using primer sets for the bfpA gene (Table 1). The number of PCR cycles used came within the linearity range for PCR amplification and constitutive expression of 16S rRNA assessed from the same cDNA preparation was used as a standard. Samples (10 μl) of each PCR product were separated by electrophoresis in 2.0% agarose and visualized by ethidium bromide staining. The bands of the bfpA gene were confirmed visually and results were standardized with the 16S rRNA band density.

[2] This potential for the bacterium

to cause disease aft

[2] This potential for the bacterium

to cause disease after inhalation and the difficulties with therapy have resulted in this pathogen being classified as a serious bio-threat agent by the US-Center for Disease Control.[6] Two case clusters of melioidosis have been reported from Australia in which a strain of B. pseudomallei isolated from a common water source was genotyped and implicated as the source of infection.[7, 8] Within each case cluster there was a diversity of clinical presentations despite the infecting strain being clonal, reflecting the importance of host risk factors and possibly also varying mode of infection such as percutaneous versus ingestion. Zoonotic, person-to-person and laboratory-acquired transmissions are all exceedingly rare, and two cases of transmission via ingestion of mastitis-associated buy Palbociclib infected breast milk[9] and cases of vertical transmission have been reported.[10] In an endemic area, severe weather events and quantum of 14-day rainfall prior to the onset of clinical illness has been shown to be an independent risk-factor for both the increased incidence of melioidosis as well as the severity of related septicaemia.[11] Many cases have been related to occupational AZD6244 exposure,

such as rice farming in Thailand[5] and garden maintenance and landscaping and outdoor trades work in Australia.[12] Melioidosis associated with sporting activities on wet, muddy sports fields is also recognized.[12] Diabetes mellitus (mainly type 2), hazardous alcohol consumption, Thiamet G chronic kidney disease and chronic lung disease have been shown to be major independent comorbid risk factors

for melioidosis.[12-15] Male preponderance was observed in all series from Australia, Thailand and Singapore.[12-15] In a population-based tropical northern Australian prospective study, estimated adjusted relative risks (95% confidence intervals) for melioidosis were 4.0 (3.2–5.1) for those aged 45 years or over, 2.4 (1.9–3.0) for men, 13.1 (9.4–18.1) for diabetics, 2.1 (1.6–2.6) for those with excess alcohol consumption, 4.3 (3.4–5.5) for chronic lung disease and 3.2 (2.2–4.8) for chronic kidney disease. Aboriginality was shown to be associated with adjusted relative risk of 3.0 (2.3–4.0), this increased risk is possibly related to increased exposure to soil and untreated fresh water.[15] In the Australian prospective study, 39% of patients with melioidosis had diabetes and 12% had chronic kidney disease, but in 20% there was no identifiable risk factor found.[12] It is established that B. pseudomallei can survive and multiply within phagocytes.[16] The comorbidities recognized as risk factors for melioidosis may be operating by impairing the innate immune system and in particular neutrophil and macrophage function.

The blood spots were extracted on ice with 25 mm Tris-HCl, pH 7 4

The blood spots were extracted on ice with 25 mm Tris-HCl, pH 7.4, 15 mm KCl, 1 mm EDTA and 1 mm dithiothreitol, and ADA and purine nucleoside phosphorylase (PNP) activities as well as total protein content were assayed as described previously [12]. An additional aliquot of the extract was treated with perchloric acid, neutralized and analysed for AXP and dAXP content; “percent dAXP” (dAXP/(AXP + dAXP) × 100) was used

to assess dAXP elevation [12]. Cell proliferation assays.  Peripheral blood mononuclear cells (PBMC) from the patient and controls were purified from whole blood using density gradient centrifugation with Ficoll-Hypaque (Sigma Aldrich) and suspended in RPMI 1640 supplemented with 2 mm l-glutamine, 50 U/ml penicillin, 50 μg/ml streptomycin and 10% human serum. PBMC at 2 × 105 from each individual were added in triplicates to 96-well

see more U-bottom plates (Falcon-Becton Dickinson, San Diego, CA, USA), and cells were stimulated with Phytohaemagglutinin (PHA; Sigma Aldrich) at 5, 10 and 20 μg/ml and cultured in a humidified incubator at 37 °C containing 5% CO2 for 86 h. One μCi of 3H-thymidine (MP Biomedicals, Irving, CA, USA) was added to each well and the cells were cultured for an additional 20 h. Cultures were harvested onto glass fibre filter papers Deforolimus mw (Inotech Biosystems Internacional Inc, Rockville, MD, USA) using an automated multisample Cell Harvester (Inotech Biosystems). Counts per minute (cpm) were measured using a liquid scintillation counter (Plate Chameleon; Multilabel reader, Hidex, Turku, Finland), and the results were expressed as proliferation index (PI), calculated by dividing the mean cpm from the triplicates of stimulated cells by the mean cpm of triplicates BCKDHB from unstimulated cells. Complementarity determining region 3 (CDR3) size distribution

analysis of T cells.  Anticoagulated whole blood was collected from the patient and three controls, treated with RNA Stabilization Reagent (Roche Diagnostics GmbH, Mannheim, Germany) and stored at −20 °C until use. Total RNA was isolated using the High Pure RNA Isolation kit (Roche Diagnostics) according to the manufacturer’s instructions, with the exception that stabilized samples were directly added to the filters instead of the initial lysis step. The cDNA was generated from 2 μg of total RNA using the SuperScript II reverse Transcriptase kit (Invitrogen, Carlsbad, CA, USA) and later used as template for PCR using 24 different unlabelled TCR Vβ primers (Gene Probe Technology, Gaithersburg, MD, USA) and a 6-fluorescein phosphoramidite (6-FAM)-labelled Cβ-specific primer (Invitrogen) that recognizes both Cβ1 and Cβ2. PCR conditions included 40 cycles of amplification at 95 °C/2 min, 95 °C for 45 s, 60 °C/45 s and 72 °C/54 s, with a final step at 72 °C/7 min.

Also we need to know more about how to attack cancer-initiating a

Also we need to know more about how to attack cancer-initiating and dormant tumor cells. The step-wise rational development of effective cancer vaccines requires coordinated networks, new procedures to get access to drugs under development to test promising combinations, and a much better task

management as currently also discussed in the USA (see www.nap.edu/catalog/12879.html). Clinical trials selleck chemical are both costly and demanding because of the ethical, logistical, and increasingly stringent regulatory requirements. As the number of trials possible is therefore limited, it is crucial to develop consensus strategies to pick the right ideas and critical variables. In the DC-THERA network (www.dc–thera.org) and the CIMT integrated project (www.cancerimmunotherapy.eu), we have been quite successful in reaching a consensus on such priorities regarding DC vaccination trials but in spite of this, obtaining sufficient financial support for such consensus trials remains a major hurdle. We as scientists https://www.selleckchem.com/products/CP-673451.html will have to put much more effort into convincing politicians as well as the public that it is crucial to invest in this field so that discoveries can be efficiently and promptly translated into therapies that are of help to the patients. We also have to

point out the crucial role of academic research as a think tank where many ideas are promoted to finally trigger the interest of investors or pharmaceutical companies. G.S. is supported by the German Science Foundation (notably SFB643), DC-THERA NoE, CIMT IP and ENCITE Collaborative Project of the EC. Conflict of interest: The author declares no financial

or commercial conflict of interest. See accompanying article: http://dx.doi.org/10.1002/eji.201040474 “
“The rodent intestinal nematode H.p.bakeri has played an important role in the exploration of see more the host–parasite relationship of chronic nematode infections for over six decades, since the parasite was first isolated in the 1950s by Ehrenford. It soon became a popular laboratory model providing a tractable experimental system that is easy to maintain in the laboratory and far more cost-effective than other laboratory nematode–rodent model systems. Immunity to this parasite is complex, dependent on antibodies, but confounded by the parasite’s potent immunosuppressive secretions that facilitate chronic survival in murine hosts. In this review, we remind readers of the state of knowledge in the 1970s, when the first volume of Parasite Immunology was published, focusing on the role of antibodies in protective immunity.

Indeed, a major recent study explicitly linked evolutionary press

Indeed, a major recent study explicitly linked evolutionary pressure of helminth infection with autoimmune disease via adaptation of the FcγR genes [117]. It supports the hygiene hypothesis, which states that in the absence of chronic helminth infection, as seen in modern first-world populations, previously selected FcγR alleles respond differently to immune system challenges and therefore alter the susceptibility

to autoimmune disease [80]. It also points towards genetic and evolutionary investigation of complex structurally variable genomic regions that contain immune genes, of which there are many [118], as an approach to finding disease susceptibility alleles. Further, the ‘antibody theory’ to explain the hygiene hypothesis is readily testable in the H. p. bakeri model, and we therefore propose a number of experiments for future investigations: IgG purified from chronic primary infected animals is better at learn more interacting with low-affinity inhibitory receptors than

IgG purified from naïve or vaccinated individuals and thus will be more effective at protecting against autoimmune disease in mouse models. Different mouse strains will exhibit genetic variability of their FcγR and SIGLECs that predict many of the immunological phenotypes discussed above, and Chronic infection leads to B cells with Nutlin3 modulated IgG–Fc glycosylation [119]. We also anticipate the discovery of H. p. bakeri glycosidases exquisitely specific for the sugars on IgG, as are known for bacteria

[120]. These may even lead to the development of new therapies for autoimmune disease as recently demonstrated for bacterial Suplatast tosilate endoglycosidase S [121]. With the rapid growth of sequencing technologies, already well under way for H. p. bakeri, the genome of the parasite is likely to be fully known in the very near future, and this information should accelerate greatly the discovery of parasite genes and their products. As mentioned above, antibodies may also prove useful in identifying parasite products that interfere with host responses, although the mechanistic role of antibodies in this process first needs to be addressed. The factors regulating antibody production also need to be identified clearly. Previous findings that different mouse strains exhibit poor or strong immunity correlating with the speed and extent of specific antibody production [64, 15, 65] highlight genetics as a major determinant of the antibody-dependent protective immune responses in this system. Today various recombinant inbred mouse lines are available for use in quantitative trait loci (QTL) studies, and these could be exploited to build on the work that has already been pioneered in inbred mouse strains [122, 123] to provide ever-refined loci for genes involved in protective and other accompanying responses.

Evidence supporting an enhanced consumption of long-chain n-3 PUF

Evidence supporting an enhanced consumption of long-chain n-3 PUFAs includes a study in which children with atopic eczema were found to have lower serum levels of EPA and DHA than non-atopic children, despite similar levels of fish consumption [2]. Results from intervention

studies have been inconclusive [13–15]. Various animal models have been used to study the role of n-3 PUFAs in atopic inflammation. Yokoyama et al. [16] showed a reduced atopic asthma reaction in a mouse model after exposure to aerosolized DHA. Yoshino and Ellis [17] reported a tendency towards reduced cell-mediated hypersensitivity reactions in mice fed a fish oil-supplemented diet. However, neither study Adriamycin in vivo noted any effect on IgE production. Yet another study reported decreased secretion of Th1-type cytokines [IFN-γ and tumour necrosis factor (TNF)-α], but enhanced secretion of the Th2 cytokine IL-4, from splenocytes in mice fed a fish oil-enriched diet [18]. The present study

was designed to investigate Ivacaftor cost the hypothesis that intake of long-chain n-3 PUFAs would affect Th1- and Th2-mediated sensitization and/or inflammation differentially. The effects of fish oil (rich in n-3 PUFAs) and sunflower oil (rich in n-6 PUFAs) intake were studied in two mouse hypersensitivity models: Th1-driven delayed-type hypersensitivity (DTH) and Th2-driven IgE production and eosinophil-mediated airway inflammation. In addition, the effect of PUFA consumption on the fatty acid serum profile was evaluated by monitoring serum levels during the study. Four-week-old male BALB/c mice (Scanbur AB, Sollentuna, Sweden) were provided with food and water ad libitum. The mice were fed with one of three diets. The control group received regular

mouse chow containing 1 wt% soya oil (Lantmännen, Lidköping, Sweden). The fish oil group received regular chow supplemented with Carteolol HCl 10 wt% fish oil containing 0·28 g EPA/ml and 0·34 g DHA/ml (Möllers Tran natural; Peter Möller, Oslo, Norway). The sunflower oil group received regular chow supplemented with 10 wt% sunflower oil containing 0·54 g linoleic acid/ml (Coop Solrosolja; Coop Sweden, Solna, Sweden). Permission for the study was granted by the Regional Ethics Committee, University of Gothenburg (no. 408-2008), and the experiments were carried out according to the guidelines of the ‘Council of Europe Convention for the Protection of Vertebrate Animals used for Experimental and Other Scientific purposes’. Th1-mediated hypersensitivity was tested in the DTH model summarized in Fig. 1a. After receiving the experimental or control diet for 21 days, the mice were anaesthetized briefly (Isofluran; Baxter Medical AB, Kista, Sweden) and then each hind leg was injected intramuscularly with 50 µg ovalbumin (OVA) in 50 µl of phosphate-buffered saline (PBS), emulsified in an equal volume of complete Freund’s adjuvant (Difco Laboratories, Detroit, MI, USA).

For obvious reasons, we did not

have renal tissue of lupu

For obvious reasons, we did not

have renal tissue of lupus patients without kidney problem to compare with. Further studies are needed to determine the pattern of intra-renal miRNA expression in relation to the histological class of lupus nephritis. This study was supported in part by the CUHK research account 6901031. All authors declare no conflict of interest. “
“The pathogenesis of systemic lupus erythematosus (SLE) entails a complex interaction between the different arms of the immune system. While autoantibodies production and immune complex deposition are cornered as hallmark features of SLE, there is growing evidence to propose the pathogenic selleck compound library role of cytokines in this disease. Examples of these cytokines include BLys, interleukin-6, interleukin-17, interleukin-18, type I interferons and tumour necrosis factor alpha. These cytokines all assume pivotal functions to orchestrate the differentiation, maturation and activation of various cell BIBW2992 types,

which would mediate local inflammatory process and tissue injury. The knowledge on these cytokines not only fosters our understanding of the disease, but also provides insights in devising biomarkers and targeted therapies. In this review, we focus on cytokines which have substantial pathogenic significance and also highlight the possible clinical applications of these cytokines. Systemic lupus erythematosus (SLE) is an autoimmune disorder which has multi-organ involvements. The pathogenesis of SLE, which involves the various facets of the immune system, is complex and perplexing. The orthodox understanding of this disease encompasses autoantibodies production and immune complex deposition, which will give rise to the subsequent Mirabegron autoimmune phenomenon. However, mounting evidence has emerged to suggest the crucial role of various cytokines in the pathogenesis of SLE. These cytokines are soluble factors which are vibrant mediators for the differentiation, maturation and activation of the various immune cells. The consequence of such would be an immune dysregulation followed by local inflammatory processes and tissue damage. The

understanding of these cytokines not only enhances our perception of SLE, but also instills novel ideas for the design of biomarkers and therapeutic agents. In this review, we highlight the cytokines which exert significant effects on the pathogenesis of SLE and their clinical applications. IL-6 is one of the first cytokines studied in the pathogenesis of SLE due to its close link with B lymphocytes. This cytokine is primarily secreted by the monocytes, fibroblasts and endothelial cells although the T- and B- lymphocytes also contribute to its production. It has an elaborated interaction with other cytokines as its levels is boosted by IL-1, IL-2 and tumour necrosis factor-α (TNF-α) but diminished by IL-4, IL-10 and IL-13.

Future directions in this field will also be discussed MiRNAs we

Future directions in this field will also be discussed. MiRNAs were first found in the nematode Caenorhabditis elegans in 1993.1 Since then they have also been described widely in plants and mammals.2 MiRNAs are first transcribed in the nucleus as stem-loop primary miRNA, which are then cleaved into shorter precursor miRNA by Drosha, an RNase III, and its essential Temozolomide cofactor called DGCR8 (DiGeorge syndrome critical region 8), a double-stranded RNA-binding protein (Fig. 1).3–6 The precursor miRNAs are transported out of the nucleus via Exportin-5 and once in the cytosol are cleaved into their mature form of 20–22 nucleotides by Dicer, another

RNase III.7,8 After cleavage, the miRNA duplex is unwound and the functional strand is loaded onto the RNA-induced silencing complex (RISC) and functions as its guide.9 The mature miRNA guides the RISC complex to a (near) complementary sequence, usually in the 3′ untranslated region (UTR), of a target messenger RNA (mRNA).9 Upon binding, the RISC causes post-transcriptional gene silencing by

either cleaving the target mRNA or by inhibiting its translation, Fulvestrant so that miRNAs are usually negative regulators of gene expression.10 In addition to their role in such post-transcriptional repression, miRNAs have now been implicated in transcriptional gene silencing by targeting the promoter region but have also been reported to have a positive effect on transcription.11–13 Each miRNA can potentially regulate the translation

of a large number of different mRNA and each mRNA can Thymidine kinase possess multiple binding sites for a single or for many different miRNA because the specificity of miRNA is mainly determined by Watson-Crick base pairing at the 5′ region of the miRNA. Estimates have suggested that the total number of different miRNA sequences in humans may exceed 1000.14 Computational analysis also predicts that over 60% of human genes are potential targets of miRNAs and that there are a large number of other non-coding RNAs of greater nucleotide length than microRNA, which are also likely to have important functions.15 However, direct experimental evidence defining mRNA targets of miRNA regulation has been reported for only a small number of miRNAs and target mRNAs. Assaying the levels of specific microRNA sequences was initially cumbersome; however, advances in technology now allow detection with a sensitivity and specificity that can enable monitoring in a clinical setting. Originally, RNA blot analyses provided both quantitative and qualitative information about the various forms of a miRNA within a total RNA sample.1,16 As the number of miRNAs in the miRBase registry17 has increased, microarray technology has been adapted to enable the parallel screening of thousands of miRNAs in one sample.18 More recently, real time reverse transcription-polymerase chain reaction has been adapted to enable relative quantification and quantitative analysis of miRNA levels.

Consequently, we are today limited to the default postulate that

Consequently, we are today limited to the default postulate that the regulation of class is determined solely by germline-selected processes [6, 8]. This can be rationalized in evolutionary terms as the origin of the effector mechanism that rids a pathogen is an outcome of the same interactive germline-selection pressures operating between pathogen and host that gave rise to the innate system. Using the Matzinger and Kamala [30] suggestion as a base, an effector class is defined here as the collection of compatible Cobimetinib elements (cell

types, interleukins, chemokines, immunoglobulins, etc.) that synergize or cooperate to rid a given category of pathogen. This will be referred to as an ‘effector ecosystem’. The elements of an ecosystem act in concert and will eventually have to be detailed. In the end, the detritus produced by the biodestrucive effector activities is ridded by macrophage phagocytosis, requiring that all effector ecosystems feed into that mechanism. Therefore, each ecosystem must include a humoral component that arms phagocytosis. The cell-mediated system might stop

INCB024360 price the development of a pathogen, but cannot rid it. As a dead reckoning estimate to simplify the discussion, there are four effector ecosystems, an initially expressed or naive effector system and three systems to which the naive effector system can switch or differentiate in response to Eliminon-driven additional signalling. Adopting a simplified nomenclature based on that used for the humoral system, these four ecosystems would be M, G, A and E. Admittedly, this nomenclature might become misleading. One should

be cautious as there may not be a totally faithful concordance between the Ig-subtype and membership in a given ecosystem. The four effector ecosystems are, at least in part, incompatible with each other because they express activities that are mutually inhibitory. For example, IgA that does not activate C’-lysis can inhibit the activation of C’-lysis by IgM or IgG2 and eTh1 can inhibit the induction of eTh2 and vice versa. Therefore, keeping the ecosystems functionally separated when responding to multiple Eliminons interacting with or derived from a given tissue is a problem that must eventually be faced [6]. The antigen-responsive cells, iT/B, are born as part of the Florfenicol M-ecosystem. It consists of virgin iTh0, iTc0, Bμ/δ and the eTh0 that are required to prime the response. Included, of course, in this ecosystem are the APCs, macrophages and several other cell types, as well as the interleukins and other factors required for induction to effectors and their functioning. As a minimum, no trauma signals need be postulated for the induction of the M-ecosystem to effectors. The M-ecosystem is the virgin or initial state. The virgin M-ecosystem has the potential to either respond as such or to differentiate to any one of the three other ecosystems, G, A or E.

HPV16 and 18 are responsible for about 90% of the

HPV16 and 18 are responsible for about 90% of the Copanlisib cell line HPV-positive anal, vulvar/vaginal and oropharyngeal cancers [90], although the estimates are less reliable for cancers other than cervix because the number of high quality HPV typing observations is much lower. It seems likely that routine HPV typing of all cases of HPV-associated cancer forms will become an essential part of the long-term evaluation/monitoring of HPV vaccination programmes

in most countries. Current HPV vaccines include only the major oncogenic types, responsible for only 70% of cervical cancers. Moreover, as the vaccines are aimed at protecting HPV-naive individuals, and the effect on already exposed women is questionable, screening will continue to be necessary [91]. Nevertheless, the reduced background risk may, after just a few decades, allow an increase of the screening intervals. It has been estimated that conventional cytological screening every 5 years starting at 30 years of age results in a 67% reduction in lifetime cervical cancer risk. Adding HPV16/18 vaccination to this programme would result in a risk reduction of 89% [92]. Obviously, several aspects

of monitoring and evaluation are the same or strongly interrelated for screening and vaccination, arguing that these complementary strategies need to be co-ordinated in a comprehensive cervical learn more cancer prevention programme [91,93,94]. Internationally comparable methods for monitoring of HPV vaccination programmes.  The global HPV LabNet has been launched by the WHO as an initiative towards global quality assurance and standardization of HPV testing methods used in follow-up of HPV vaccination programmes (http://www.who.int/biologicals/vaccines/hpv/en/index.html). International collaborative

studies have been performed for both HPV serology [95] and HPV DNA testing and typing [96]. The results indicate that methods clonidine are comparatively robust, provided that measurements are related to the same international standard serum that is assayed in parallel [95]. For both HPV antibodies and HPV DNA tests, WHO reference reagent of anti-HPV 16 antibody and the first WHO international standards for HPV types 16 and 18 DNA are available from the WHO International Laboratory for Biological Standards in the UK (http://www.nibsc.ac.uk/products.aspx); other biological reference standards that will facilitate interlaboratory comparison and harmonize laboratory testing via defining an international unit of measurement are being pursued. For quality assurance, and as a basis for certification, global proficiency panels will be made available. An ‘HPV laboratory manual’ that will provide quality assurance/quality control guidance, basic validated assay protocols and examples of state-of-the-art methods is being developed at WHO.